Dr AlbertLockhart by Ángel Minaya https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c en-us 2024-03-01 13:33:19 UTC 2024-03-04 13:56:30 UTC hello@padlet.com Life angelminayasanchez https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902017401

A. Craig Lockhart, M.D., M.H.S., new Director of the Division of Hematology & Oncology, effective April 1. He will also serve as Associate Director for Clinical Science at MUSC Hollings Cancer Center (HCC). Dr. Lockhart’s experience as an academic leader, clinical trialist, and esteemed member of the medical oncology community will serve him well as he leads the division and HCC to new heights.

]]> 2024-03-01 13:59:02 UTC https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902017401 Studies angelminayasanchez https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902019439
Dr. Lockhart graduated from the University of Texas Southwestern Medical School at Dallas in 1993. He completed residency training at Barnes Hospital at Washington University, fellowship training in hematology/oncology at Duke University, and a fellowship in drug development at GlaxoSmithKline in the North Carolina Research Triangle Park. He also earned a master's of health science (MHS) in clinical trials at Duke University. He completed his undergraduate degree, a bachelor's degree in biology, from Rice University.

]]> 2024-03-01 14:00:40 UTC https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902019439 Important contributions angelminayasanchez https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902021946 He has been conducting early phase clinical trials for over 20 years and has been a principal investigator on over 100 Phase I/II and III trials. His specific research interests are to develop and conduct Phase I/II clinical trials of novel therapeutics applied to his specialty area of research, gastrointestinal cancers. In treating these cancers, he aims to incorporate novel agents or molecular/genetic based treatment into therapeutic trials in the pursuit of personalized cancer care. He has developed and led multi-institutional clinical trials involving the treatment of GI tumors through national cooperative groups as well as investigator-initiated studies. He has been an investigator and co-investigator on individual grants, on successful SPORE grant applications and on successful multi-institutional UM1 grant applications.

]]> 2024-03-01 14:02:43 UTC https://padlet.com/angelminayasanchez/18fw1vyrnicf6n1c/wish/2902021946